🇺🇸 FDA

Drug profile · INN

zaleplon

SONATA

FDA: approved EMA: withdrawn N05CF03
US status
approved
Patents linked
2
News articles
0

Quick answer

zaleplon (SONATA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN zaleplon
Brand SONATA
Route ORAL
Formulation CAPSULE
ATC code N05CF03
Originator Teva Pharma GmbH

Related patents

Search patents →

  1. US 7348429

    Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process

    Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 6884888

    Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)

    Expires Mon Apr 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is zaleplon?

zaleplon (SONATA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for zaleplon?

SONATA is a marketed brand name for zaleplon. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of zaleplon?

zaleplon has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.